Abstract
Abstract Gastric cancer (GC), the second leading cause of cancer-related deaths worldwide, is especially prevalent in Asian countries. Despite advances in therapeutics, GC patients with peritoneal metastasis is frequent and when ascites has developed, the prognosis is very poor. Also, the number of anticancer drugs successfully marketed is rare in GC. Therefore, a faithfully in vitro model that can test various drugs and perform patient-specific personalized therapy is needed. We isolated cancer cells from ascites or pleural fluids of gastric cancer patients and established 19 patient-derived organoids and matched patient-derived cancer cell lines (PDCC). Organoid success rate was 60.7 % while PDCC was about 28.5 %. The time required to establish organoids was 1-2 months, while PDCC was 3-4 months. Organoids showed various growth characteristics and morphology, which reflects the clinical behavior of the patients including adenocarcinoma or signet ring cell carcinoma. In addition, drug-sensitive to each organoid and matched PDCC were identified using various chemotherapeutics and targeted agents. Then, patients' clinical information and comparative analysis were performed, suggesting the potential sensitive drug to each patient. Currently, the genetic information of each organoid is ongoing with WES/RNA Seq, and the sensitivity and comparative analysis of the drug will be performed. Therefore, our results provide a potential infrastructure for personalized therapy by comprehensive analysis of the patient's genomic data and organoid/PDCC model. Citation Format: Sun Kyoung Kang, Hyun Joo Bae, Woo Sun Kwon, Tae Soo Kim, Sujin Lee, Sang Woo Cho, Hyun Cheol Chung, Sun Young Rha. Establishment of organoids and patient derived cancer cell lines from gastric cancer body fluids as preclinical models for personalized therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2973.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
